Press Releases
- XCE853 is Oregon Therapeutic’s first-in-class, and potentially best-in-class PDI inhibitor, exhibiting potent preclinical efficacy across multiple solid and hematological cancers, and is ready to advance to Investigational New Drug (IND)-enabling development.
- The AI-enabled collaboration aims to refine and expand the positioning of XCE853, a novel protein disulfide isomerase (PDI) inhibitor, in new and targeted oncology indications, including for drug-resistant... (continue reading...)
HONG KONG, May 6, 2024 /PRNewswire/ -- OKX Ventures, the investment arm of leading crypto exchange and Web3 technology company OKX, has announced a strategic investment in four consumer-oriented products from Web3 venture studio EVG. These include multi-chain SocialFi infrastructure Open Social Protocol, decentralized collaboration network Zeek, strategy card game Legend of Arcadia and real-time strategy game Last Odyssey.
WOODBURY, Minn. & ST. LOUIS--(BUSINESS WIRE)-- Kindeva Drug Delivery (Kindeva), a global leader in drug-device combination products, today announced its investment in a second manufacturing line for the production of pressurized metered-dose inhaler (pMDI) products containing low-GWP (Global Warming Potential) propellants in its Loughborough, U.K., facility.
This new line will be capable of handling both HFA-152a and HFO-1234ze propellants — that have a GWP of... (continue reading...)
NEW TAIPEI CITY, Taiwan--(BUSINESS WIRE)-- The SINOX Group will showcase the brand-new technology, the Synlox e-security system, at this year's Eurobike exhibition. This initiative leads the traditional lock industry and aims to provide E-bikes with more comprehensive protection.
SINOX Group will showcase the brand-new technological innovation - the Synlox e-security system at the 2024 Eurobike exhibition. Synlox represents an advanced E-bike security solution,... (continue reading...)
Now in beta, Rimsys Intel will leverage the strong expertise of RAPS RAC holders as part of an innovative, community-driven approach to regulatory intelligence.
BERLIN--(BUSINESS WIRE)-- Rimsys, a leading regulatory information management software for the medtech industry, announced today the beta launch of its community-driven, centralized hub for global regulatory intelligence data, Rimsys Intel. Rimsys Intel builds upon Rimsys’ mission of increasing the... (continue reading...)
More Press Releases
View Older Stories-
SINOX Group to Showcase Universal Laptop Locks Aligning with the AI Era at Computex Taipei 2024
-
Oma Savings Bank Plc: Manager´s Transactions – Closely associated person Tanja Mäkynen
-
Oma Savings Bank Plc: Manager´s Transactions – Jyrki Mäkynen
-
Share buy-back programme - week 18
-
Elbit Systems Schedules First Quarter 2024 Results Release For May 28, 2024
-
INRED and SES to Provide High-Throughput Connectivity Across Colombia’s Amazonas
-
LHV Pank to contest the fine decision by Estonian Financial Intelligence Unit
-
Renault Group: Communication related to the availability of the EMTN base prospectus 2024
-
Transactions in connection with share buyback programme
-
Preliminary data on early redemptions (prepayments)
-
Pierre Anjolras appointed Chief Operating Officer of VINCI
-
Marimekko celebrates the 60th anniversary of the Unikko print in Helsinki and Tokyo with public open-air fashion shows
-
QUADIENT: 2024 Financial calendar - Update
-
Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
-
Exor Press Release - Periodic Report on the Buyback Program
-
Graphano Expands Zone 3 at LAB Graphite Project - Reports Remaining Program Results including 15.65 Metres Grading 7.91% Cg
-
KKR to Acquire Healthium from Apax Funds
-
TerraPay Continues to Attract Top Industry Talent, Names Hassan Chatila as Vice President and Global Head of Network
-
BrainChip and Frontgrade Gaisler to Augment Space-Grade Microprocessors with AI Capabilities
-
Xylem Unveils 'Reuse Brew'
-
SES to acquire Intelsat: Investor Relations Frequently Asked Questions
-
Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca
-
Health Canada Approves Nexstim NBS 6 System for Treatment of MDD
-
Aktsiaselts Infortar interim report for Q1 2024
-
Fingerprints and Infrafon collaborating on new smart badges for the European Medical and IoT market
-
Subsea7 share repurchases
-
M&P Receives a Specific License From the OFAC in Relation to Its Operations in Venezuela
-
Statement Concerning Eutelsat Group’s Ground Network
-
Ambri Agrees to Terms of Proposed Sale with Lender Consortium
-
BGHL (GBP): NAV(s)
-
BGHL (EUR): NAV(s)
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
Transaction in Own Shares
-
Declaration of shares and voting rights April 30, 2024 - VALNEVA SE
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
-
Start of Day Message
-
Market Update
-
Sohu.com to Report First Quarter 2024 Financial Results on May 20, 2024
-
CARMAT Continues to Build on Its Momentum in the EFICAS Study and Reiterates Confidence in Its 2024 Outlook
-
Elliptic Labs Shipping on vivo V30e Smartphone
-
Subc – Ex. Dividend Nok 3.00 Today
-
Press Release Biocartis NV: Biocartis and Merck to Collaborate on Improving Patient Access to Personalized Medicine in Middle East and North Africa (MEA) Region